CN Patent

CN110088091A — 19-去甲c3,3-二取代的c21-n-吡唑基类固醇的晶体

Assigned to Sage Therapeutics Inc · Expires 2019-08-02 · 7y expired

What this patent protects

本发明涉及式(I)的19‑去甲C3,3‑二取代的C21‑吡唑基类固醇，及其结晶固体形式和组合物。本文还公开了制备式(I)的19‑去甲C3,3‑二取代的C21‑吡唑基类固醇的结晶固体形式的方法和使用式(I)的19‑去甲C3,3‑二取代的C21‑吡唑基类固醇或结晶固体形式、其药学上可接受的盐和药学上可接受的组合物的方法。

USPTO Abstract

本发明涉及式(I)的19‑去甲C3,3‑二取代的C21‑吡唑基类固醇，及其结晶固体形式和组合物。本文还公开了制备式(I)的19‑去甲C3,3‑二取代的C21‑吡唑基类固醇的结晶固体形式的方法和使用式(I)的19‑去甲C3,3‑二取代的C21‑吡唑基类固醇或结晶固体形式、其药学上可接受的盐和药学上可接受的组合物的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN110088091A
Jurisdiction
CN
Classification
—
Expires
2019-08-02
Drug substance claim
No
Drug product claim
No
Assignee
Sage Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.